Shanghai Cell Therapy Group Co., Ltd.
🇭🇰Hong Kong, China
- Country
- 🇭🇰Hong Kong, China
- Ownership
- Holding, Subsidiary
- Established
- 2013-11-29
- Employees
- 1.1K
- Market Cap
- -
- Website
- http://www.shcell.com
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
Early Phase 1
Recruiting
- Conditions
- RelapsedRefractoryMultiple Myeloma
- Interventions
- Drug: CD19/CD20/BCMA CAR-T
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT06732232
- Locations
- 🇨🇳
China, Shanghai Mengchao Cancer Hospital, Shanghai, China
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)
Early Phase 1
Active, not recruiting
- Conditions
- Non-Hodgkin Lymphoma, B-cell
- Interventions
- Biological: CD19/CD20/BCMA CAR T cells
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT06446128
- Locations
- 🇨🇳
Mengchao Cancer Hospital, Shanghai, Shanghai, China
An Exploratory Study by Fast CAR T Cells
Early Phase 1
Recruiting
- Conditions
- Solid Tumor
- Interventions
- Biological: Fast CAR T cells
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT06327997
- Locations
- 🇨🇳
Shanghai Mengchao Cancer Hospital, Shanghai, Shanghai, China
An Exploratory Study on the Treatment of Advanced Solid Tumors by Fast CAR T Cells
Early Phase 1
Recruiting
- Conditions
- Solid Tumor
- Interventions
- Biological: Fast CAR T cells
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT06249256
- Locations
- 🇨🇳
Shanghai Mengchao Cancer Hospital, Shanghai, Shanghai, China
Exploratory Study of MSLN-CAR T Cells Secreting PD1/CTLA-4 Nanoantibody for the Treatment of Advanced Solid Tumors
Early Phase 1
Recruiting
- Conditions
- Solid Tumor
- Interventions
- Biological: αPD1/CTLA4-MSLN-CAR T cells
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT06248697
- Locations
- 🇨🇳
Shanghai Mengchao Cancer Hospital, Shanghai, Shanghai, China
The Exploratory Study About the Effect of Using Double Filtration Plasmapheresis (DFPP) Removing Inflammatory Cytokines, Lipids and Toxic Metal Ions in Peripheral Blood in Adults
Not Applicable
Not yet recruiting
- Conditions
- Sub-healthyToxic Metal Ions AccumulationHyperlipidemia
- Interventions
- Device: DFPP
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
- Target Recruit Count
- 250
- Registration Number
- NCT06224296
- Locations
- 🇨🇳
Shanghai Mengchao Cancer Hospital, Shanghai, Shanghai, China
The Exploratory Study on the Biological Function of Dendritic Cells In Vivo Supported by Nicotinamide Mononucleotide (Vital NAD)
Early Phase 1
Not yet recruiting
- Conditions
- Postoperative Prevention of Tumor
- Interventions
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT06036355
- Locations
- 🇨🇳
Shanghai Mengchao Cancer Hospital, Shanghai, Shanghai, China
Exploratory Study on Baize DC Injection in Preventing Recurrence and Metastasis After Radical Tumor Surgery
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
- Target Recruit Count
- 200
- Registration Number
- NCT06015269
- Locations
- 🇨🇳
Shanghai Mengchao Cancer Hospital, Shanghai, Shanghai, China
The Exploratory Study on the Baseline Level of NAD+/NADH in Peripheral Blood Samples of Different Gender and Age Groups of Healthy Adults.
Not yet recruiting
- Conditions
- NAD+/NADH in Peripheral Blood Monitoring
- Interventions
- Other: Detection of NAD+/NADH concentration of Peripheral Blood Samples
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT05997628
- Locations
- 🇨🇳
Shanghai Mengchao Cancer Hospital, Shanghai, Shanghai, China
The Exploratory Study on the Nicotinamide Mononucleotide (Vital NAD ) to Promote the Rejuvenation of the Peripheral Blood Immune Cells of Adults.
Early Phase 1
Not yet recruiting
- Conditions
- Enhance Immune Function
- Interventions
- Drug: NMN
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
- Target Recruit Count
- 10
- Registration Number
- NCT05984550
- Locations
- 🇨🇳
Shanghai Mengchao Cancer Hospital, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath